{"id":589,"date":"2026-05-14T15:54:59","date_gmt":"2026-05-14T14:54:59","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=589"},"modified":"2026-07-02T22:28:37","modified_gmt":"2026-07-02T21:28:37","slug":"fbs-vs-human-serum","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/fbs-vs-human-serum\/","title":{"rendered":"FBS im Vergleich zu Humanserum"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"589\" class=\"elementor elementor-589\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-38cbbaf e-con e-atomic-element e-flexbox-base e-4899a9a \" data-id=\"38cbbaf\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"38cbbaf\">\n    \t\t<div class=\"elementor-element elementor-element-f802228 elementor-widget elementor-widget-html\" data-id=\"f802228\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!--\nYOAST SEO \u00b7 Slug: \/products\/fetal-bovine-serum\/fbs-vs-human-serum\/\nSEO Title: FBS vs. Human Serum | When to Switch | Complete Guide | SeamlessBio\nMeta Desc: FBS vs. Human Serum \u2014 complete application guide. When to switch, performance comparison, xeno-free requirements, CAR-T, primary cells and ATMP manufacturing. SeamlessBio.\n-->\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\": \"ListItem\", \"position\": 1, \"name\": \"Home\", \"item\": \"https:\/\/www.seamlessbio.de\/\"}, {\"@type\": \"ListItem\", \"position\": 2, \"name\": \"FBS\", \"item\": \"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/\"}]},{\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\": \"Question\", \"name\": \"When should I switch from FBS to human serum?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Switch to human serum when: (1) Working with human primary cells that perform better in a physiological human matrix. (2) Application requires xeno-free documentation (ATMP, cell therapy). (3) Running T-cell, MLR or ELISPOT assays where bovine IgG causes background. (4) CAR-T or PBMC culture requiring human AB serum. (5) Regulatory submission requires xeno-free ancillary material justification.\"}}, {\"@type\": \"Question\", \"name\": \"Can human serum replace FBS at the same concentration?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"For most human primary cell applications yes \\u2014 5\\u201310% human serum as a direct replacement for 5\\u201310% FBS. For CAR-T expansion, 5% human AB serum is standard. However, human serum and FBS have different growth factor profiles: off-the-clot human serum has higher PDGF, EGF and TGF-\\u03b2 than standard plasma-derived FBS. A qualification step comparing cell growth in both sera is always recommended before switching.\"}}, {\"@type\": \"Question\", \"name\": \"Is human serum more expensive than FBS?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Yes \\u2014 human serum is typically 3\\u20138\\u00d7 more expensive than FBS per litre due to donor screening requirements, lower collection volumes and higher regulatory compliance costs. For applications where FBS performs equivalently, there is no benefit to switching. The switch is justified when xeno-free documentation is required or when cell performance is demonstrably better in human serum.\"}}]}]}<\/script>\n<div class=\"sbp-page\"><div class=\"sbp-wrap\">\n<nav class=\"sbp-bc\"><a href=\"https:\/\/www.seamlessbio.de\/\">Home<\/a><span>\/<\/span><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/\">FBS<\/a><span>\/<\/span><strong>FBS vs. Human Serum<\/strong><\/nav>\n<div class=\"sbp-hero\">\n  <span class=\"sbp-eyebrow\">Selection Guide \u00b7 FBS \u00b7 Human Serum \u00b7 When to Switch<\/span>\n  <h1>FBS vs. Human Serum \u2014 Complete Selection Guide<\/h1>\n  <p>The choice between fetal bovine serum (FBS) and human serum is application-driven. This guide covers the key differences in composition, performance and regulatory compliance \u2014 with specific recommendations for cell culture, immunology, ATMP manufacturing and IVD development.<\/p>\n  <div class=\"sbp-tags\"><span>Application Guide<\/span><span>FBS 9 Grades<\/span><span>Human Serum 10 Variants<\/span><span>Xeno-Free<\/span><span>ATMP<\/span><\/div>\n  <div class=\"sbp-btns\">\n    <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/\" class=\"sbp-btn\">View FBS Range<\/a>\n    <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/\" class=\"sbp-btn-o\">View Human Sera<\/a>\n  <\/div>\n<\/div>\n\n<div class=\"sbp-section\">\n<h2 class=\"sbp-h2\">Key Differences at a Glance<\/h2>\n<table class=\"sbp-table\">\n<tr><th>Parameter<\/th><th>Fetal Bovine Serum (FBS)<\/th><th>Human Serum<\/th><\/tr>\n<tr><td>Source<\/td><td>Bovine fetal blood \u2014 USA, Australia, NZ, South America<\/td><td>Adult human donors \u2014 EU and US donor centres<\/td><\/tr>\n<tr><td>IgG content<\/td><td>Very low (0.1\u20131 mg\/mL standard; &lt;50 \u00b5g\/mL Ultra-Low IgG)<\/td><td>High (7\u201316 mg\/mL normal range) \u2014 unless IgG-depleted<\/td><\/tr>\n<tr><td>Growth factors<\/td><td>High (PDGF, EGF, IGF-1, FGF) \u2014 especially OTC human serum has higher PDGF<\/td><td>OTC human serum: highest natural growth factor content<\/td><\/tr>\n<tr><td>Xeno-free status<\/td><td>Animal-derived \u2014 not xeno-free<\/td><td>Human-derived \u2014 xeno-free for human cell applications<\/td><\/tr>\n<tr><td>Regulatory status<\/td><td>TSE\/BSE documentation required. GMP pathway with origin documentation<\/td><td>Donor screening per EU blood directive. IVDR documentation available<\/td><\/tr>\n<tr><td>Cost (typical)<\/td><td>Lower \u2014 standard cost baseline<\/td><td>3\u20138\u00d7 higher per litre<\/td><\/tr>\n<tr><td>Batch variation<\/td><td>Lot qualification recommended<\/td><td>Pooled lots \u2014 lower donor-to-donor variation<\/td><\/tr>\n<tr><td>Processing (SeamlessBio)<\/td><td>Germany (Passau)<\/td><td>Germany (Passau)<\/td><\/tr>\n<\/table>\n<\/div>\n\n<div class=\"sbp-alt\">\n<h2 class=\"sbp-h2\">Application-Specific Recommendation<\/h2>\n<table class=\"sbp-table\">\n<tr><th>Application<\/th><th>Recommended<\/th><th>Reason<\/th><\/tr>\n<tr><td>CHO, HEK293, Vero, MDCK \u2014 routine culture<\/td><td>FBS Standard<\/td><td>Cost-effective, well-validated, no xeno-free requirement<\/td><\/tr>\n<tr><td>Hybridoma \u2014 mAb production<\/td><td>FBS Heat Inactivated<\/td><td>Complement inactivation; low IgG for clean antibody purification<\/td><\/tr>\n<tr><td>ES\/iPSC maintenance<\/td><td>FBS ES Cell Pre-Tested or Human Serum OTC<\/td><td>Application-specific lot qualification critical<\/td><\/tr>\n<tr><td>Naive hPSC culture<\/td><td>NaivaCore + FBS ES or Human Serum<\/td><td>HENSM protocol requires specific serum supplement<\/td><\/tr>\n<tr><td>PBMC isolation & culture<\/td><td>Human Serum AB or Human Serum Male<\/td><td>Xeno-free; no HLA alloantibodies for immunological assays<\/td><\/tr>\n<tr><td>CAR-T T-cell expansion<\/td><td>Human Serum OTC Type AB Male<\/td><td>Maximum growth factors + AB compatibility + HLA alloantibody-free<\/td><\/tr>\n<tr><td>MSC expansion (research)<\/td><td>FBS Standard or Human Platelet Lysate<\/td><td>FBS for research; hPL preferred for GMP-adjacent<\/td><\/tr>\n<tr><td>MSC expansion (GMP)<\/td><td>Human Platelet Lysate (hPL)<\/td><td>Xeno-free, GMP-compatible, 3\u20135\u00d7 higher MSC proliferation<\/td><\/tr>\n<tr><td>ATMP manufacturing<\/td><td>Human Serum Cell Culture Grade or hPL<\/td><td>Xeno-free ancillary material required for regulatory submission<\/td><\/tr>\n<tr><td>IVD calibrator matrix<\/td><td>Human Serum Standard or Delipidated<\/td><td>Physiological human matrix; IVDR documentation available<\/td><\/tr>\n<tr><td>Immunoassay blocking<\/td><td>FBS Low Endotoxin or Human Serum Standard<\/td><td>Depends on assay antibody species; match serum to antibody origin<\/td><\/tr>\n<tr><td>ELISA, cytokine assays<\/td><td>Human Serum Standard<\/td><td>Human matrix eliminates xenogenic protein interference<\/td><\/tr>\n<\/table>\n<\/div>\n\n<div class=\"sbp-section\">\n<h2 class=\"sbp-h2\">When to Switch from FBS to Human Serum<\/h2>\n<div class=\"sbp-grid-3\">\n<div class=\"sbp-card\"><h3>Xeno-Free Requirement<\/h3><p>ATMP and cell therapy manufacturing under IVDR or GMP regulations increasingly requires xeno-free ancillary materials. Human serum or hPL replaces FBS with a regulatory-compliant, human-derived alternative.<\/p><\/div>\n<div class=\"sbp-card\"><h3>Human Primary Cell Performance<\/h3><p>Some human primary cells \u2014 particularly haematopoietic cells, T-cells and endothelial cells \u2014 show significantly better growth, viability and function in human serum versus FBS due to physiological compatibility.<\/p><\/div>\n<div class=\"sbp-card\"><h3>Immunological Assay Interference<\/h3><p>Bovine IgG in FBS can cross-react with anti-human secondary antibodies in ELISAs and western blots. Human serum Ultra-Low IgG or FBS Ultra-Low IgG eliminates this interference.<\/p><\/div>\n<div class=\"sbp-card\"><h3>T-Cell & Immunology Assays<\/h3><p>For MLR, ELISPOT and antigen-specific T-cell assays, human serum male (HLA alloantibody-free) eliminates pregnancy-induced antibody interference that can suppress antigen-specific responses.<\/p><\/div>\n<div class=\"sbp-card\"><h3>CAR-T Manufacturing<\/h3><p>Industry standard for CAR-T T-cell expansion is 5% human AB serum \u2014 universal blood type compatibility and xeno-free status. Human OTC AB Male is the premium format combining growth factors, AB type and HLA alloantibody-free status.<\/p><\/div>\n<div class=\"sbp-card\"><h3>IVD Calibrator Development<\/h3><p>IVD calibrators require human serum matrix to accurately reflect patient sample composition. Human serum with IVDR documentation is the only correct matrix for immunoassay calibrators designed for human diagnostic use.<\/p><\/div>\n<\/div>\n<\/div>\n\n<div class=\"sbp-section\">\n<h2 class=\"sbp-h2\">Frequently Asked Questions<\/h2>\n<div class=\"sbp-faq\"><h3>When should I switch from FBS to human serum?<\/h3><p>Switch when: working with human primary cells requiring physiological matrix, application requires xeno-free documentation (ATMP), running T-cell assays where bovine IgG causes background, CAR-T or PBMC culture requiring human AB serum, or regulatory submission requires xeno-free ancillary material justification.<\/p><\/div>\n<div class=\"sbp-faq\"><h3>Can human serum replace FBS at the same concentration?<\/h3><p>For most human primary cells \u2014 yes, 5\u201310% direct replacement. A qualification step is always recommended. Human OTC serum has higher PDGF, EGF and TGF-\u03b2 than standard plasma-derived FBS, so growth kinetics may differ.<\/p><\/div>\n<div class=\"sbp-faq\"><h3>Is human serum more expensive than FBS?<\/h3><p>Yes \u2014 typically 3\u20138\u00d7 higher per litre. The switch is justified when xeno-free documentation is required or when cell performance is demonstrably better in human serum for your specific application.<\/p><\/div>\n<\/div>\n\n<div class=\"sbp-cta\"><h2>Request Samples of Both \u2014 Compare Directly<\/h2><p>Free test samples of FBS and human serum. No minimum order. Lot reservation without prepayment. 48-hour quote.<\/p><div class=\"sbp-cta-btns\"><a href=\"https:\/\/www.seamlessbio.de\/about-us\/contact-imprint\/\" class=\"sbp-btn\">Request Samples<\/a><a href=\"https:\/\/shop.seamlessbio.de\" class=\"sbp-btn-o\">Visit Shop<\/a><\/div><\/div>\n<\/div><\/div>\n<style>\n.sbp-page,.sbp-page *{box-sizing:border-box}\n.sbp-page{font-family:Arial,sans-serif;color:#202020;background:#fff;padding:60px 0 90px}\n.sbp-wrap{max-width:1400px;margin:0 auto;padding:0 40px}\n.sbp-bc{display:flex;flex-wrap:wrap;gap:6px;align-items:center;font-size:13px;color:#999;margin-bottom:32px}\n.sbp-bc a{color:#18b7b2!important;text-decoration:none!important;font-weight:600}.sbp-bc span{color:#ddd}\n.sbp-hero{background:#f7fbfb;border:1px solid rgba(24,183,178,.15);border-radius:24px;padding:52px;margin-bottom:56px}\n.sbp-eyebrow{display:inline-block;font-size:12px;font-weight:800;letter-spacing:.1em;text-transform:uppercase;color:#18b7b2;margin-bottom:14px}\n.sbp-hero h1{font-size:42px;font-weight:900;letter-spacing:-.02em;margin:0 0 16px;color:#202020;line-height:1.1}\n.sbp-hero p{font-size:17px;line-height:1.7;color:#555;margin:0 0 24px;max-width:780px}\n.sbp-tags{display:flex;flex-wrap:wrap;gap:8px;margin-bottom:28px}\n.sbp-tags span{background:rgba(24,183,178,.08);border:1px solid rgba(24,183,178,.2);border-radius:20px;padding:5px 14px;font-size:12px;font-weight:700;color:#18b7b2}\n.sbp-btns{display:flex;gap:12px;flex-wrap:wrap}\n.sbp-btn{display:inline-block;background:#18b7b2;color:#fff!important;font-weight:700;font-size:14px;padding:13px 28px;border-radius:999px;text-decoration:none!important}\n.sbp-btn-o{display:inline-block;background:#fff;color:#18b7b2!important;font-weight:700;font-size:14px;padding:12px 28px;border-radius:999px;border:2px solid #18b7b2;text-decoration:none!important}\n.sbp-h2{font-size:26px;font-weight:800;color:#202020;margin:0 0 20px;padding-bottom:12px;border-bottom:2px solid #18b7b2;display:inline-block}\n.sbp-intro{font-size:15px;line-height:1.75;color:#555;margin:0 0 24px;max-width:860px}\n.sbp-section{margin-bottom:56px}.sbp-alt{background:#f7fbfb;border-radius:20px;padding:44px;margin-bottom:56px}\n.sbp-grid-3{display:grid;grid-template-columns:repeat(3,1fr);gap:20px}\n.sbp-grid-2{display:grid;grid-template-columns:1fr 1fr;gap:28px}\n.sbp-grid-4{display:grid;grid-template-columns:repeat(4,1fr);gap:16px}\n.sbp-card{background:#fff;border:1.5px solid rgba(24,183,178,.18);border-radius:18px;padding:24px}\n.sbp-card h3{font-size:15px;font-weight:800;color:#202020;margin:0 0 8px}\n.sbp-card p{font-size:13px;line-height:1.65;color:#555;margin:0}\n.sbp-card-link{display:block;text-decoration:none!important;background:#fff;border:1.5px solid rgba(24,183,178,.18);border-radius:18px;padding:24px;transition:all .2s}\n.sbp-card-link:hover{border-color:#18b7b2;transform:translateY(-3px)}\n.sbp-card-link h3{font-size:15px;font-weight:800;color:#18b7b2;margin:0 0 8px}\n.sbp-card-link p{font-size:13px;line-height:1.6;color:#555;margin:0}\n.sbp-table{width:100%;border-collapse:collapse;font-size:14px}\n.sbp-table th{background:#18b7b2;color:#fff;padding:11px 16px;text-align:left;font-weight:700}\n.sbp-table td{padding:11px 16px;border-bottom:1px solid #eee;vertical-align:top}\n.sbp-table tr:nth-child(even) td{background:#f7fbfb}\n.sbp-table td:first-child{font-weight:700;color:#202020}\n.sbp-ul{list-style:none;padding:0;margin:0}\n.sbp-ul li{font-size:14px;line-height:1.6;color:#555;padding:8px 0 8px 20px;border-bottom:1px solid #eef7f6;position:relative}\n.sbp-ul li::before{content:\"\u2014\";position:absolute;left:0;color:#18b7b2;font-weight:700}\n.sbp-ul li strong{color:#202020}\n.sbp-cta{background:linear-gradient(135deg,#0d9490 0%,#18b7b2 60%,#1ec8c2 100%);border-radius:24px;padding:52px;text-align:center;color:#fff;margin-top:56px}\n.sbp-cta h2{font-size:26px;font-weight:900;margin:0 0 12px;color:#fff;border:none;display:block}\n.sbp-cta p{font-size:16px;color:rgba(255,255,255,.9);margin:0 0 28px}\n.sbp-cta-btns{display:flex;justify-content:center;gap:14px;flex-wrap:wrap}\n.sbp-cta .sbp-btn{background:#fff;color:#18b7b2!important}\n.sbp-cta .sbp-btn-o{border-color:rgba(255,255,255,.6);color:#fff!important;background:transparent}\n.sbp-faq{padding:18px 0;border-bottom:1px solid rgba(24,183,178,.15)}\n.sbp-faq h3{font-size:16px;font-weight:700;color:#202020;margin:0 0 8px}\n.sbp-faq p{font-size:14px;line-height:1.7;color:#555;margin:0}\n.sbp-step{display:flex;gap:18px;padding:20px;background:#fff;border:1.5px solid rgba(24,183,178,.18);border-radius:14px;margin-bottom:12px}\n.sbp-step-num{flex-shrink:0;width:36px;height:36px;background:#18b7b2;color:#fff;border-radius:50%;display:flex;align-items:center;justify-content:center;font-size:15px;font-weight:800}\n.sbp-step h3{font-size:15px;font-weight:700;color:#202020;margin:0 0 6px}\n.sbp-step p{font-size:13px;line-height:1.6;color:#555;margin:0}\n.sbp-compare-hero{display:grid;grid-template-columns:1fr auto 1fr;gap:24px;align-items:center;margin-bottom:32px}\n.sbp-compare-vs{width:48px;height:48px;background:#18b7b2;color:#fff;border-radius:50%;display:flex;align-items:center;justify-content:center;font-size:14px;font-weight:900;flex-shrink:0}\n@media(max-width:1024px){.sbp-grid-3{grid-template-columns:1fr 1fr}.sbp-grid-4{grid-template-columns:1fr 1fr}}\n@media(max-width:768px){.sbp-wrap{padding:0 20px}.sbp-hero{padding:32px 20px}.sbp-grid-3,.sbp-grid-2,.sbp-grid-4{grid-template-columns:1fr}.sbp-alt{padding:24px 18px}.sbp-compare-hero{grid-template-columns:1fr}}\n<\/style>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home\/FBS\/FBS vs. Human Serum Selection Guide \u00b7 FBS \u00b7 Human Serum \u00b7 When to Switch FBS vs. Human Serum \u2014 Complete Selection Guide The choice between fetal bovine serum (FBS) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-589","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FBS vs. Human Serum | When to Switch | SeamlessBio<\/title>\n<meta name=\"description\" content=\"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP &amp; primary human cells. EMA\/410\/01 guidance explained.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/fbs-vs-human-serum\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FBS vs. Human Serum | When to Switch | SeamlessBio\" \/>\n<meta property=\"og:description\" content=\"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP &amp; primary human cells. EMA\/410\/01 guidance explained.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/fbs-vs-human-serum\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T21:28:37+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-human-serum\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-human-serum\\\/\",\"name\":\"FBS vs. Human Serum | When to Switch | SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-05-14T14:54:59+00:00\",\"dateModified\":\"2026-07-02T21:28:37+00:00\",\"description\":\"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP & primary human cells. EMA\\\/410\\\/01 guidance explained.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-human-serum\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-human-serum\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-human-serum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FBS vs. Human Serum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FBS vs. Human Serum | When to Switch | SeamlessBio","description":"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP & primary human cells. EMA\/410\/01 guidance explained.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/fbs-vs-human-serum\/","og_locale":"de_DE","og_type":"article","og_title":"FBS vs. Human Serum | When to Switch | SeamlessBio","og_description":"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP & primary human cells. EMA\/410\/01 guidance explained.","og_url":"https:\/\/seamlessbio.de\/de\/fbs-vs-human-serum\/","og_site_name":"SeamlessBio","article_modified_time":"2026-07-02T21:28:37+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/fbs-vs-human-serum\/","url":"https:\/\/seamlessbio.de\/fbs-vs-human-serum\/","name":"FBS vs. Human Serum | When to Switch | SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-05-14T14:54:59+00:00","dateModified":"2026-07-02T21:28:37+00:00","description":"FBS vs human serum comparison for cell culture. When to switch for CAR-T, ATMP & primary human cells. EMA\/410\/01 guidance explained.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-human-serum\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/fbs-vs-human-serum\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/fbs-vs-human-serum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"FBS vs. Human Serum"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"},"image":{"@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=589"}],"version-history":[{"count":8,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/589\/revisions"}],"predecessor-version":[{"id":2266,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/589\/revisions\/2266"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}